The Common Path of Prostate Cancer: A Specialist's Guide

Receiving a prostate cancer diagnosis can bring up many questions about what comes next. Understanding the typical journey, or “path,” of the disease can help provide clarity during a confusing time. This guide breaks down the common progression of prostate cancer, explaining each stage as a medical specialist would.

The First Step: Diagnosis and Staging

The journey for nearly every patient begins with diagnosis. For many men, this process is initiated by routine screening or the emergence of urinary symptoms. Specialists follow a clear process to confirm the presence of cancer and determine its characteristics.

  • Initial Screening: The path often starts with a Prostate-Specific Antigen (PSA) blood test. PSA is a protein produced by the prostate gland, and elevated levels can indicate a problem, including cancer. Another common screening tool is the Digital Rectal Exam (DRE), where a doctor feels the prostate for any hard or lumpy areas.
  • Confirmation with a Biopsy: If screening results are suspicious, the definitive diagnostic step is a prostate biopsy. A urologist uses a thin needle to take small tissue samples from the prostate. These samples are then sent to a pathologist.
  • The Pathologist’s Report: Gleason Score: The pathologist’s analysis is crucial. They examine the cancer cells under a microscope and assign a Gleason score. This score, typically ranging from 6 to 10, grades how abnormal the cancer cells look. A lower score (like 6) indicates a less aggressive, slow-growing cancer, while a higher score (8 to 10) signifies a more aggressive cancer that is likely to grow and spread more quickly. This score is one of the most important factors in deciding the next steps.
  • Staging the Cancer: Once cancer is confirmed, specialists “stage” it to understand how far it has progressed. They use the TNM system (Tumor, Nodes, Metastasis) to describe the size of the tumor, whether it has spread to nearby lymph nodes, and if it has spread (metastasized) to distant parts of the body.

The Next Stage: Managing Localized Prostate Cancer

The vast majority of men are diagnosed when the cancer is still confined to the prostate gland. This is called localized prostate cancer. At this point, the path often splits into two main directions, depending on the risk level determined by the PSA level, Gleason score, and clinical stage.

Path 1: Active Surveillance for Low-Risk Cancer

For men with a low Gleason score (typically 6) and a small amount of slow-growing cancer, the most common recommendation is often not immediate treatment. Instead, specialists recommend a program called active surveillance. This is not the same as doing nothing; it is a proactive approach to closely monitor the cancer.

Active surveillance typically involves:

  • Regular PSA tests (e.g., every 3 to 6 months).
  • Repeat DREs (e.g., annually).
  • Follow-up biopsies or MRI scans at scheduled intervals to check for any changes.

The goal is to avoid or delay the side effects of treatment for as long as possible, since many of these low-risk cancers grow so slowly they may never cause a problem in a man’s lifetime. Treatment is only initiated if there are signs the cancer is becoming more aggressive.

Path 2: Definitive Treatment for Higher-Risk Cancer

For men with more aggressive or higher-volume localized cancer (e.g., Gleason score of 7 or higher), specialists usually recommend definitive treatment aimed at curing the disease. The two primary treatment options are:

  • Surgery (Radical Prostatectomy): A surgeon removes the entire prostate gland. This can be done through open surgery or, more commonly, with robotic-assisted laparoscopic techniques, which are less invasive.
  • Radiation Therapy: This uses high-energy rays to destroy cancer cells. It can be delivered from a machine outside the body (External Beam Radiation Therapy) or by placing radioactive seeds inside the prostate (Brachytherapy).

The choice between these treatments depends on a man’s age, overall health, and personal preferences after a detailed discussion with his medical team.

A Potential Detour: Biochemical Recurrence

After treatment with surgery or radiation, some men experience what is called a “biochemical recurrence.” This is not a clinical diagnosis of visible cancer but is defined by a rising PSA level.

For a man who had a prostatectomy, any detectable PSA can signal a recurrence. For a man who had radiation, doctors look for a specific rise in PSA over its lowest point. A rising PSA suggests that some cancer cells remained in the body and are starting to grow again. The next step is usually imaging scans, like a PSMA PET scan, to try and locate where the cancer is. Treatment at this stage, called salvage therapy, might involve radiation (if surgery was the first treatment) or other systemic therapies.

The Path to Advanced Disease

If prostate cancer spreads beyond the prostate gland, it is considered advanced or metastatic. The most common place for it to spread is to the lymph nodes and bones. The goal of treatment at this stage shifts from a cure to controlling the cancer’s growth, managing symptoms, and extending life.

The cornerstone of treatment for advanced prostate cancer is Androgen Deprivation Therapy (ADT), also known as hormone therapy. Prostate cancer cells use testosterone (an androgen) as fuel to grow. ADT works by dramatically lowering the testosterone levels in the body, which effectively starves the cancer cells and causes them to shrink or stop growing for a period of time. This is usually administered through injections.

While ADT is very effective, most prostate cancers eventually adapt and start to grow again even with very low testosterone levels. This is known as Castration-Resistant Prostate Cancer (CRPC). When this happens, the path involves moving to other treatments, such as more advanced hormone therapies (like abiraterone or enzalutamide), chemotherapy, targeted therapies, or radiopharmaceuticals, to continue controlling the disease.

Frequently Asked Questions

What are the most common symptoms of prostate cancer? In its early stages, prostate cancer often has no symptoms. As it grows, it can cause issues like difficulty urinating, a weak urine stream, blood in the urine or semen, and erectile dysfunction. However, these symptoms are more commonly caused by non-cancerous conditions like an enlarged prostate (BPH).

Is prostate cancer always a slow-growing disease? No. While many prostate cancers are slow-growing and may not require immediate treatment, some forms are very aggressive and can spread quickly. The Gleason score from a biopsy is the best tool specialists use to determine how aggressive a particular cancer is.

Does every man with prostate cancer follow this exact path? This guide describes the most common progression, but every patient’s journey is unique. The specific path depends on the cancer’s characteristics, the patient’s age and overall health, and decisions made in consultation with a team of medical specialists, including urologists and oncologists.